Bioventus Inc. (NASDAQ: BVS) reported Q4 EPS of $0.24, $0.04 better than the analyst estimate of $0.20. Revenue for the quarter came in at $157.9 million versus the consensus estimate of $156.08 million.

GUIDANCE:

Bioventus Inc. sees FY2026 EPS of $0.73-$0.77, versus the consensus of $0.77. Bioventus Inc. sees FY2026 revenue of $600-610 million, versus the consensus of $604.2 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.